P-CD19CD20-ALLO1

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameP-CD19CD20-ALLO1
Drug Alias NameDual P-CD19CD20-ALLO1 Allogeneic CAR-T therapyDual CD19/CD20 CAR T therapyCD19/CD20 CAR T-cell therapyDual CD19/CD20 targeting CAR-T therapyP-CD19CD20-ALLO1
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-CD19 +[4] 
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicMultiple Sclerosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPoseida Therapeutics IncGenentech Inc
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLupus Erythematosus, SystemicMultiple Sclerosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A